{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T22:43:43Z","timestamp":1725230623232},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00108-015-3667-2","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T13:37:56Z","timestamp":1426081076000},"page":"391-405","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapie der Hepatitis\u00a0C"],"prefix":"10.1007","volume":"56","author":[{"given":"M.D.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Kronenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,13]]},"reference":[{"key":"3667_CR1","first-page":"298A","volume":"60","author":"Mantry","year":"2014","unstructured":"Mantry P, Kwo PY, Coakley E et\u00a0al (2014) High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype\u00a01 infection receiving ABT-450\/r\/Ombitasvir + Dasabuvir plus Ribavirin. Hepatology 60:298A\u2013299A","journal-title":"Hepatology"},{"key":"3667_CR2","doi-asserted-by":"crossref","unstructured":"Wedemeyer H, Duberg AS, Buti M et\u00a0al (2014) Strategies to manage hepatitis\u00a0C virus (HCV) disease burden. J\u00a0Viral Hepat 21(Suppl\u00a01):60\u201389","DOI":"10.1111\/jvh.12249"},{"key":"3667_CR3","doi-asserted-by":"crossref","unstructured":"Poordad F, Hezode C, Trinh R et\u00a0al (2014) ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis\u00a0C with cirrhosis. N\u00a0Engl J Med 370:1973\u20131982","DOI":"10.1056\/NEJMoa1402869"},{"key":"3667_CR4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","volume":"9","author":"Backus","year":"2011","unstructured":"Backus LI, Boothroyd DB, Phillips BR et\u00a0al (2011) A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis\u00a0C. Clin Gastroenterol Hepatol 9:509\u2013516.e501","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3667_CR5","doi-asserted-by":"crossref","unstructured":"Sarrazin C, Berg T, Wedemeyer H et\u00a0al (2014) Aktuelle Empfehlung der DGVS zur Therapie der chronischen Hepatitis\u00a0C. Deutsche Gesellschaft f\u00fcr Verdauungs- und Stoffwechselkrankheiten (DGVS)","DOI":"10.1055\/s-0033-1362589"},{"key":"3667_CR6","doi-asserted-by":"crossref","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M et\u00a0al (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N\u00a0Engl J Med 370:211\u2013221","DOI":"10.1056\/NEJMoa1306218"},{"key":"3667_CR7","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.2014.12627","volume":"312","author":"Meer","year":"2014","unstructured":"Meer AJ van der, Wedemeyer H, Feld JJ et\u00a0al (2014) Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312:1927\u20131928","journal-title":"JAMA"},{"key":"3667_CR8","doi-asserted-by":"crossref","unstructured":"Ruane PJ, Ain D, Meshrekey R et\u00a0al (2014) Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype\u00a04 HCV infection. Abstracts of the International Liver Congress\u2122 2014 \u2013 49th Annual Meeting of the European Association for the Study of the Liver. J\u00a0Hepatol 60:S503\u2013S504","DOI":"10.1016\/S0168-8278(14)61403-3"},{"key":"3667_CR9","doi-asserted-by":"crossref","unstructured":"Afdhal N, Reddy KR, Nelson DR et\u00a0al (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype\u00a01 infection. N\u00a0Engl J Med 370:1483\u20131493","DOI":"10.1056\/NEJMoa1316366"},{"key":"3667_CR10","first-page":"239A","volume":"60","author":"Bourlie","year":"2014","unstructured":"Bourlie\u0300re M, Sulkowski M, Omata M et\u00a0al (2014) An integrated safety and efficacy analysis of >\u2009500\u00a0patients with compensated cirrhosis treated with ledipasvir\/sofosbuvir with or without ribavirin. Hepatology 60:239A","journal-title":"Hepatology"},{"key":"3667_CR11","doi-asserted-by":"crossref","unstructured":"Kowdley KV, Gordon SC, Reddy KR et\u00a0al (2014) Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N\u00a0Engl J Med 370:1879\u20131888","DOI":"10.1056\/NEJMoa1402355"},{"key":"3667_CR12","first-page":"1141A","volume":"60","author":"Jacobson","year":"2014","unstructured":"Jacobson I, Kwo P, Kowdley K et\u00a0al (2014) Virologic response rates to all oral fixed-dose combination ledipasvir\/sofosbuvir regimens are similar in patients with and without traditional negative predictive factors in phase\u00a03 clinical trials. Hepatology 60(4 Suppl\u00a01):1141A","journal-title":"Hepatology"},{"key":"3667_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","volume":"147","author":"Andreone","year":"2014","unstructured":"Andreone P, Colombo MG, Enejosa JV et\u00a0al (2014) ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 and 100\u2009% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype\u00a01b infection. Gastroenterology 147:359\u2013365.e351","journal-title":"Gastroenterology"},{"key":"3667_CR14","doi-asserted-by":"crossref","unstructured":"Feld JJ, Kowdley KV, Coakley E et\u00a0al (2014) Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N\u00a0Engl J Med 370:1594\u20131603","DOI":"10.1056\/NEJMoa1315722"},{"key":"3667_CR15","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Jacobson IM, Baykal T et\u00a0al (2014) Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N\u00a0Engl J Med 370:1604\u20131614","DOI":"10.1056\/NEJMoa1401561"},{"key":"3667_CR16","doi-asserted-by":"crossref","unstructured":"Ferenci P, Bernstein D, Lalezari J et\u00a0al (2014) ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N\u00a0Engl J Med 370:1983\u20131992","DOI":"10.1056\/NEJMoa1402338"},{"key":"3667_CR17","first-page":"238A","volume":"60","author":"Fried","year":"2014","unstructured":"Fried M, Forns X, Reau N et\u00a0al (2014) TURQUOISE-II: regimens of ABT-450\/r\/ombitasvir and dasabuvir with ribavirin achieve high svr12 rates in HCV genotype\u00a01-infected patients with cirrhosis, regardless of baseline characteristics. Hepatology 60:238A","journal-title":"Hepatology"},{"key":"3667_CR18","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R et\u00a0al (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis\u00a0C virus genotype\u00a01 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756\u20131765","journal-title":"Lancet"},{"key":"3667_CR19","first-page":"220A","volume":"60","author":"Dieterich","year":"2014","unstructured":"Dieterich D, Bacon B, Flamm S et\u00a0al (2014) Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 60:220A","journal-title":"Hepatology"},{"key":"3667_CR20","first-page":"219A","volume":"58","author":"Jensen","year":"2014","unstructured":"Jensen D, O\u2019Leary J, Pockros P et\u00a0al (2014) Safety and efficacy of sofosbuvir-containing regimens for hepatitis\u00a0C: real-world experience in a diverse, longitudinal observational cohort. Hepatology 58:219A\u2013220A","journal-title":"Hepatology"},{"key":"3667_CR21","doi-asserted-by":"crossref","unstructured":"Gane EJ, Stedman CA, Hyland RH et\u00a0al (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis\u00a0C. N\u00a0Engl J Med 368:34\u201344","DOI":"10.1056\/NEJMoa1208953"},{"key":"3667_CR22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","volume":"310","author":"Osinusi","year":"2013","unstructured":"Osinusi A, Meissner EG, Lee YJ et\u00a0al (2013) Sofosbuvir and ribavirin for hepatitis\u00a0C genotype\u00a01 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 310:804\u2013811","journal-title":"JAMA"},{"key":"3667_CR23","doi-asserted-by":"crossref","unstructured":"Jacobson IM, Gordon SC, Kowdley KV et\u00a0al (2013) Sofosbuvir for hepatitis\u00a0C genotype\u00a02 or 3 in patients without treatment options. N\u00a0Engl J Med 368:1867\u20131877","DOI":"10.1056\/NEJMoa1214854"},{"key":"3667_CR24","doi-asserted-by":"crossref","unstructured":"Lawitz E, Mangia A, Wyles D et\u00a0al (2013) Sofosbuvir for previously untreated chronic hepatitis\u00a0C infection. N\u00a0Engl J Med 368:1878\u20131887","DOI":"10.1056\/NEJMoa1214853"},{"key":"3667_CR25","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Dusheiko GM, Salupere R et\u00a0al (2014) Sofosbuvir and ribavirin in HCV genotypes\u00a02 and 3. N\u00a0Engl J Med 370:1993\u20132001","DOI":"10.1056\/NEJMoa1316145"},{"key":"3667_CR26","first-page":"LB","volume":"58","author":"Nelson","year":"2014","unstructured":"Nelson D, Cooper J, Lalezari J et\u00a0al (2014) All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT)\u00a03: ALLY-3 phase\u00a03 study. Hepatology 58:LB\u2013L3","journal-title":"Hepatology"},{"key":"3667_CR27","doi-asserted-by":"crossref","unstructured":"Gane E, Hyland R, An D et\u00a0al (2014) Ledipasvir\/sofosbuvir fixed-dose combination is safe and effective in difficult-to-treat populations including GT\u00a03 patients, decompensated GT\u00a01 patients, and GT\u00a01 patients with prior sofosbuvir experience. J\u00a0Hepatol 60:S3\u2013S4","DOI":"10.1016\/S0168-8278(14)60008-8"},{"key":"3667_CR28","first-page":"LB","volume":"60","author":"Gane","year":"2014","unstructured":"Gane E, Hyland R, An D et\u00a0al (2014) High efficacy of LDV\/SOF regimens for 12\u00a0weeks for patients with HCV genotype\u00a03 or 6 infection. Hepatology 60:LB\u2013L11","journal-title":"Hepatology"},{"key":"3667_CR29","first-page":"91A","volume":"60","author":"Kapoor","year":"2014","unstructured":"Kapoor R, Kohli A, Sidharthan S et\u00a0al (2014) Treatment of hepatitis\u00a0C genotype\u00a04 with ledipasvir and sofosbuvir for 12\u00a0weeks: results of the SYNERGY trial (oral presentation). Hepatology 60:91A","journal-title":"Hepatology"},{"key":"3667_CR30","first-page":"1129A","volume":"60","author":"Pol","year":"2014","unstructured":"Pol S, Reddy K, Baykal T et\u00a0al (2014) Interferon-free regimens of ombitasvir and ABT-450\/r with or without ribavirin in patients with HCV genotype\u00a04 infection: PEARL-I study results. Hepatology 60:1129A","journal-title":"Hepatology"},{"key":"3667_CR31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","volume":"13","author":"Lawitz","year":"2013","unstructured":"Lawitz E, Lalezari JP, Hassanein T et\u00a0al (2013) Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes\u00a01, 2, and 3 hepatitis\u00a0C infection: a randomised, double-blind, phase\u00a02 trial. Lancet Infect Dis 13:401\u2013408","journal-title":"Lancet Infect Dis"},{"key":"3667_CR32","first-page":"LB","volume":"60","author":"Bourli\u00e8re","year":"2014","unstructured":"Bourli\u00e8re M, Bronowicki J, Ledinghen V de et\u00a0al (2014) Ledipasvir\/sofosbuvir fixed-dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology 60:LB-L6","journal-title":"Hepatology"},{"key":"3667_CR33","first-page":"91A","volume":"60","author":"Flamm","year":"2014","unstructured":"Flamm S, Everson G, Charlton M et\u00a0al (2014) Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 60:91A","journal-title":"Hepatology"},{"key":"3667_CR34","doi-asserted-by":"crossref","first-page":"200A","DOI":"10.1002\/hep.27449","volume":"60","author":"Reddy","year":"2014","unstructured":"Reddy K, Everson GT, Flamm S et\u00a0al (2014) Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 60:200A\u2013201A","journal-title":"Hepatology"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-015-3667-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-015-3667-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-015-3667-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T21:43:22Z","timestamp":1566423802000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-015-3667-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,13]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3667"],"URL":"https:\/\/doi.org\/10.1007\/s00108-015-3667-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,13]]}}}